Durable and deep response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report

Introduction

Paragangliomas (PGLs) are rare neuroendocrine tumors with high heritability (1). Around half of PGLs are linked to mutations in succinate dehydrogenase subunit x (SDHx) genes (2, 3). Among these, SDHB mutations are the most common (1). SDHB-mutated PGLs present distinct clinical and biochemical features that may guide personalized therapy (1, 4–6). Here, we report a case of SDHB-mutated metastatic PGL, demonstrating significant tumor shrinkage and complete symptom remission following cyclophosphamide-vincristine-dacarbazine (CVD) chemotherapy. This case aims to contribute further evidence to the understanding of SDHB-mutated PGLs.

Case presentation

In August 2022, a 40-year-old male Asian patient, presented at the emergency department with syncope, diaphoresis, sialorrhea, absence of tic, and urinary and fecal incontinence. He displayed facial edema, a heart rate of 98 beats per minute (bpm), a blood pressure of 193/114 mm Hg, a respiratory rate of 20 breaths per minute, a body mass index of 24.2 kg/m2, and an Eastern Cooperative Oncology Group (ECOG) score of 2. 1 hours later, he gradually regained consciousness. Approximately 7 months prior to this event, he began experiencing recurring hypoglycemia at night. Over the preceding six months, he suffered recurrent headaches and his self-measured systolic blood pressure at onset exceeded 180 mmHg. Besides, there is no significant medical, familial, or psychosocial history.

Routine blood tests, liver and kidney function assessments, ECG, and cranial CT scans revealed no abnormalities. Serum levels of insulin, C-peptide, insulin-like growth factor I (IGF-I), and growth hormone (GH) were normal when blood glucose was 1.5 mmol/L (Table 1). However, thorax-abdomen CT identified a 14.1×9.7 cm left retroperitoneal mass and multiple pulmonary lesions (Figures 1A, D, G, J). Catecholamine, ACTH, and NSE levels were elevated (Table 1), aligning with a diagnosis of metastatic PGL. Although hyperglycemia is common in PPGL due to excessive catecholamine secretion, this patient experienced recurrent hypoglycemia, prompting us to further confirm the diagnosis through pathology. Additionally, imaging showed multiple lung metastases, ruling out curative surgery. Thus, the patient and family opted for a retroperitoneal lesion biopsy after discussing the biopsy risks. Fortunately, no adverse reactions occurred. Immunohistochemical analysis showed positive expression of Synaptophysin (Syn), Chromogranin A (CgA), and SSTR2, but negative for SDHB and S100 (Figure 2), with a Ki67 labeling index of 60%. Next-generation sequencing (NGS) revealed a somatic copy number loss of the SDHB gene. 68Ga-DOTATATE and 18F-FDG positron emission tomography (PET-CT) scans were conducted. The results revealed that the metastasis affected the lungs and skeletal sites, including the anterior segment of the left 7th rib, left scapula, and left humerus (Figure 3).

Table 1. Levels of serum insulin, C-peptide, IGF-I, GH and β-hydroxybutyrate during episode of hypoglycaemia.

Figure 1. (A, D, G, J) Prior to CVD chemotherapy, CT revealed retroperitoneal lesions around the pancreas, liver, kidney and multiple diffuse lesions in both lungs. (B, E, H, K) After 2 cycles of CVD chemotherapy, CT revealed that retroperitoneal lesions around the pancreas, liver, kidney and multiple diffuse lesions in both lungs reduced in size. (C, F, I, L) After 20 cycles of CVD chemotherapy, CT revealed retroperitoneal lesions further reduced in size. Although a small amount of lung lesions enlarged and new lesions appeared, the majority of lung lesions reduced in number and size. [Red arrows indicate shrinking lesions, yellow arrows indicate enlarged lesions, and green arrows indicate new lesions.].

Figure 2. Pathological findings of the retroperitoneal lesion. (A) Haematoxylin and eosin staining. (B) Ki67 positive rate was 60%. (C) The expression of SDHB was negative.

Figure 3. (A–F) Prior to CVD chemotherapy, 18F-FDG positron emission tomography (PET-CT) revealed increased uptake of 18F-FDG in the left retroperitoneal mass, lung masses and humeral head. The maximum cross-sectional area of the left retroperitoneal mass was approximately 166 × 99mm, with maximum SUV sizes of 21.49. (G–L) Prior to CVD chemotherapy, 68Ga-DOTATATE PET-CT revealed increase uptake of 68Ga-DOTATATE in the left retroperitoneal mass, lung masses and humeral head. The maximum SUV sizes of the left retroperitoneal mass was 36. 94.

Despite 1 month of symptomatic therapies, including alpha blockade and intravenous fluid replacement, recurrent hypoglycemia and hypertensive crises persisted. The progression of the disease was presumed to be rapid based on the time when the patient became aware of symptoms. Given the patient’s unresponsive state and the tumor’s rapid growth, chemotherapy was initiated under critical conditions. A combination of cyclophosphamide (1300 mg, day 1, every 4 weeks), vincristine (2 mg, day 1, every 4 weeks), and dacarbazine (1000 mg, day 1-2, every 4 weeks) was started in September 2022.Surprisingly, a CT scan revealed significant regressions of the retroperitoneal mass and lung metastases (Figures 1B, E, H, K) after two treatment cycles. According to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), a partial response (PR) was achieved. Additionally, a completely biochemical response with symptom remission was observed, allowing the cessation of symptomatic therapies (Supplementary Figure 1). NSE and catecholamine levels decreased concurrently (Supplementary Figure 1). In September 2024, CT scan revealed new pulmonary lesions and some lung lesion enlarged, suggesting disease progression. However, retroperitoneal lesions and the majority of lung lesions further reduced in size (Figures 1C, F, I, L). The progression-free survival (PFS) of CVD chemotherapy was 24 months. Given the high SSTR expression, a switch to somatostatin analogue (SSA) therapy is recommended. The patient remains stable without symptoms or treatment-related adverse effects.

Discussion

In this case, we report a 40-year-old male patient with SDHB-mutated metastatic PGL. A rapid, deep and durable PR, and complete biochemical response were achieved after CVD chemotherapy.

The prevalence of the SDHB mutated PGLs among Chinese patients has been well-documented (7, 8). Compared to others, PGL with SDHB mutation typically exhibit an early onset, noradrenergic or dopaminergic biochemical phenotype, and shorter survival (9, 10). Additionally, precision medicine can be tailored based on the SDHB mutation status. Several studies have proved that CVD chemotherapy was the first-line treatment for PGL individuals with SDHB-mutation (11, 12). Our case reaffirms above points.

Missense mutations and truncating mutations are the most commonly reported types of SDHB mutations in PGLs (13). Compared to missense mutations, truncating mutations in SDHB are typically associated with a higher malignancy potential in PPGLs (14). In our study, the patient had a SDHB mutation characterized by a copy number loss, a mutation type that has not been widely reported in previous studies. While missense mutations and truncating mutations often lead to a complete loss of the biological function of key proteins, copy number loss typically results in a reduction in gene expression, causing partial functional loss. Whether this mutation type is associated with a better prognosis in patients remains to be confirmed through large-scale clinical studies.

Notably, SDHB mutation differs from the negative immunohistochemical expression of SDHB (15). Consequently, the lack of immunohistochemical expression of SDHB is often utilized as an alternative marker in assessing SDHx gene mutations (15–21). This approach is not only cost-effective but also aids in identifying false negative results from genetic testing. However, we believe that the negative immunohistochemical expression of SDHB cannot replace next-generation sequencing. Many studies have shown that different mutations in the SDHx gene often exhibit different clinical manifestations, which are of great significance for the prognosis and treatment of patients (22, 23). Therefore, we emphasize the significance of incorporating both genetic testing and immunohistochemical analysis in clinical practice for precise diagnosis and prognosis.

Due to the hyperglycemic effect of catecholamines, hypoglycemia directly induced by PGLs is exceedingly rare. We reviewed related profiles and concluded four mechanisms to identify the mechanisms underlying this hypoglycemia (Supplementary Table S1) (24–33). Firstly, tumor autoimmune hypoglycemia, often associated with myeloma and Hodgkin’s disease (34, 35). Secondly, liver, adrenal, or pituitary insufficiency also can contribute to hypoglycemia. Thirdly, a massive tumor burden may lead to rapid glucose consumption and subsequent hypoglycemia (29). Furthermore, the production of hypoglycemic substances by tumor, such as IGF-II, IGF-I and GH, can cause hypoglycemia (36). In our case, tumor- autoimmune hypoglycemia antibodies, liver function, adrenal function, and pituitary function were all normal, thus excluding the first two mechanisms. Given the patient’s high tumor burden and the improvement of hypoglycemia as the tumor shrank, the latter two mechanisms were assumed to be involved. Rapidly growing tumors consume glucose and release hypoglycemic substances, causing the rare complication of hypoglycemia. However, due to technical limitations and our current understanding, we unfortunately did not measure serum IGF-II levels during hypoglycemia. Therefore, we can only speculate that the causes of this hypoglycemia are likely multifactorial.

Conclusion

This study presents a rare case of SDHB-mutated metastatic PGLs, demonstrating a rapid, deep and durable response to CVD chemotherapy. It underscored the critical role of SDHB mutations in influencing both prognosis and treatment selection for PGLs.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Ethics Committee on Biomedical Research, West China Hospital of Sichuan University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.

Author contributions

CZ: Writing – review & editing, Writing – original draft. YW: Writing – review & editing. KC: Visualization, Methodology, Funding acquisition, Writing – review & editing, Resources. DC: Supervision, Funding acquisition, Writing – review & editing, Resources, Conceptualization, Data curation.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2024.1483516/full#supplementary-material

References

2. Currás-Freixes M, Piñeiro-Yañez E, Montero-Conde C, Apellániz-Ruiz M, Calsina B, Mancikova V, et al. Pheoseq: A targeted next-generation sequencing assay for pheochromocytoma and paraganglioma diagnostics. J Mol diagnostics: JMD. (2017) 19:575–88. doi: 10.1016/j.jmoldx.2017.04.009

PubMed Abstract | PubMed Abstract | Crossref Full Text | Google Scholar

3. Ben Aim L, Pigny P, Castro-Vega LJ, Buffet A, Amar L, Bertherat J, et al. Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. J Med Genet. (2019) 56:513–20. doi: 10.1136/jmedgenet-2018-105714

PubMed Abstract | PubMed Abstract | Crossref Full Text | Google Scholar

5. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with Malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. (2007) 92:3822–8. doi: 10.1210/jc.2007-0709

PubMed Abstract | PubMed Abstract | Crossref Full Text | Google Scholar

6. Cui Y, Ma X, Wang F, Wang H, Zhou T, Chen S, et al. Differences in clinical manifestations and tumor features between metastatic pheochromocytoma/paraganglioma patients with and without germline sdhb mutation. Endocrine practice: Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists. (2021) 27:348–53. doi: 10.1016/j.eprac.2020.09.015

PubMed Abstract | PubMed Abstract | Crossref Full Text | Google Scholar

9. Taïeb D, Nölting S, Perrier ND, Fassnacht M, Carrasquillo JA, Grossman AB, et al. Management of phaeochromocytoma and paraganglioma in patients with germline sdhb pathogenic variants: an international expert consensus statement. Nat Rev Endocrinol. (2024) 20:168–84. doi: 10.1038/s41574-023-00926-0